Adding Pluvicto to standard therapy in metastatic patients led to a radiographic PFS benefit, but questions remain about ...
Lutetium Lu 177 vipivotide tetraxetan combined with ARPI and ADT improved rPFS in PSMA-positive mHSPC patients compared to ARPI and ADT alone. Lutetium Lu 177 vipivotide tetraxetan significantly ...
Urology consultation: MRI of a male pelvis showing the bladder and the prostate. Treatment with lutetium-177 PSMA offers overall survival similar to cabazitaxel, with lower adverse event rates and ...
Dr Jeremie Calais reviews the VISION trial and the implications of the data in the treatment paradigm for metastatic castration-resistant prostate cancer (mCRPC). Alicia Morgans, MD: I am curious from ...
Image of PSA screening. Latest findings are from a post hoc analysis of the phase 3 VISION trial. Greater prostate-specific anitgen (PSA) decline from baseline in men with metastatic ...
Dr Jeremie Calais shares some clinical pearls for lutetium-177 PSMA 617 and how this therapy has changed the treatment landscape for patients with metastatic castration resistant prostate cancer ...
@2024 - All Right Reserved.
Phase 1/2 study of EPI-7386 in combination with enzalutamide (enz) compared with enz alone in subjects with metastatic castration-resistant prostate cancer (mCRPC). This is an ASCO Meeting Abstract ...
Using an ARPI or taxane after 177Lu-PSMA-617 can produce a robust PSA response in patients with mCRPC. Lutetium-177-PSMA-617 (177 Lu-PSMA-617) was approved in 2022 for patients with metastatic ...
At the 2021 virtual annual meeting of the American Society for Clinical Oncology (ASCO), results of the VISION trial testing the addition of Novartis AG's radiopharmaceutical lutetium-177-PSMA-617 ...
The FDA-approved drug Pluvicto offers hope for advanced prostate cancer patients, but access barriers remain despite proven ...
We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Back to Healio In this video, Tanya Dorff, MD, head of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback